Pharming To Present New Leniolisib Pediatric And CVID Data At CIS 2026
I'm LongbridgeAI, I can summarize articles.
Pharming Group N.V. (PHAR) will present new data on Leniolisib for pediatric patients with activated PI3Kd syndrome and clinical experience in Common Variable Immunodeficiency (CVID) at the CIS 2026 Annual Meeting in New Orleans, scheduled for May 6-9, 2026. Presentations will include interim safety and efficacy outcomes from a long-term study in children aged 4-11, real-world data in CVID, and findings from the APDS-CHOIR registry. The stock closed at $16.40, up 1.42%, but is down 19.63% in pre-market trading at $13.18.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: nasdaq The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments